Home > Riviste > Minerva Ortopedica e Traumatologica > Fascicoli precedenti > Minerva Ortopedica e Traumatologica 2020 September;71(3) > Minerva Ortopedica e Traumatologica 2020 September;71(3):117-23

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Minerva Ortopedica e Traumatologica 2020 September;71(3):117-23

DOI: 10.23736/S0394-3410.20.03988-0

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

An open, supplement, registry study Arborvitae® for prevention of arthrosis-related pain during exercise

Shuh HU 1, 2, 3, Gianni BELCARO 1, 2, 3 , Morio HOSOI 1, 2, 3, Maria R. CESARONE 1, 2, 3, Valeria SCIPIONE 1, Claudia SCIPIONE 1, Mark DUGALL 1, 2, 3, Beatrice FERAGALLI 2, Roberto COTELLESE 2, Claudia MAIONE 1, 2, 3, Roberta LUZZI 1, 2, 3

1 Irvine3 Labs, Pescara, Italy; 2 Dept SMOBiotec, Ch-Pe University, Pescara, Italy; 3 IA-PSS (International Agency for Pharma-Standard Supplements), Pescara, Italy



BACKGROUND: This open registry study evaluated improvements in symptoms associated with osteoarthrosis (OA) managed with a standardized liquid supplement (Arborvitae®, Australia [ABV]).
METHODS: Two comparable groups of subjects using standard management (SM) for OA were evaluated: one with SM only and another using SM and supplemented with Arborvitae® 100 mL/day for 8 weeks followed by 60 mL/day for 4 weeks. Arborvitae Supplement® contains Pycnogenol®, papain and, as accessory components, Aloe Vera, procyanidins, and honey. SM was an evaluation reference. The aim of this study was the evaluation of the efficacy of Arborvitae® supplementation on signs/symptoms, particularly pain while walking and in reducing the need for rescue medications in osteoarthritis patients.
RESULTS: The two groups were comparable at inclusion. Sixty subjects completed the study: 30 in the SM group as controls and 30 in the Arborvitae® group. No tolerability problems or side effects were observed during the observation period. At 3 months, the walking distance was significantly higher in the ABV group in comparison with the control group (P<0.05). The Karnofsky Scale in the supplemented subjects improved more in the ABV group at 3 months (P<0.05); blood oxidative stress was lower with ABV in comparison with controls (P<0.05). The increased temperature of the knee (measurable by thermography) was decreased more with the supplement (P<0.05) considering the maximum temperature of the area and the average temperature of the skin over the affected knee (P<0.05). The use of rescue medications was significantly lower in the ABV group.
CONCLUSIONS: This registry indicates that ABV may be an effective supplementary management in controlling mild-moderate signs/symptoms associated with OA in otherwise healthy subjects.


KEY WORDS: Osteoarthritis; Knee joint; Cartilage; Dietary supplements; Pain; Ultrasonography

inizio pagina